Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer

Fig. 7

Predictive biomarker signature validation. A Workflow detailing the collection process for fresh biopsies and FFPE samples for bulk RNA sequencing and subsequent data processing. B Composition of samples in the MD Anderson cohort (n = 89). The cutoff for early versus late progression was 6 months. C KM plots illustrating mPFS time in the signature-high group compared to the -low group were generated using fresh biopsy RNA-seq data from the MD Anderson cohort (n = 35) and (D) FFPE RNA-seq data from the MD Anderson cohort (n = 54). KM plots, shown with the mPFS duration, were generated utilizing all 13 upregulated gene signatures for tissue samples and 10 upregulated gene signatures for FFPE samples, respectively. E Composition of samples in the Korean cohort (n = 61). F Utilizing bulk RNA-seq data from the Korean cohort (n = 61), we generated KM plots with the indicated mPFS durations utilizing 8 upregulated gene signatures. Log-rank test p-values are displayed

Back to article page

Molecular Cancer

ISSN: 1476-4598